What question did this study set out to answer?

To assess how aspirin alone or combined at different doses with dipyridamole affects platelet survival in insulin-dependent diabetic patients with severe retinopathy.

August 1, 1982Clinical Science

Aspirin, Dipyridamole and Platelet Survival in Patients with Diabetes Mellitus

View Full Paper

Ask AI

Bookmark

Why the study?

Does aspirin alone or in combination with dipyridamole prolong platelet survival in insulin-dependent diabetic patients with severe retinopathy?

Population

27 insulin-dependent diabetic patients with severe retinopathy

Comparison

Aspirin alone, or a combination of dipyridamole… vs Placebo

Design

RCT, cross-over trial, double-blind

Authors

HTH TindallLeeds General Infirmary RPR C PatonColorado State University GMGeorge P. McNicolLeeds General Infirmary

Discussion

Member takes

Implication

High-dose aspirin/dipyridamole prolongs platelet survival in diabetic retinopathy; supports ~1 g/day dosing on this surrogate but needs outcome trials.

Key Points

To assess how aspirin alone or combined at different doses with dipyridamole affects platelet survival in insulin-dependent diabetic patients with severe retinopathy.
Conducted a double-blind cross-over trial in 27 insulin-dependent diabetic patients with severe retinopathy evaluating placebo, aspirin (990 mg/day), and dipyridamole (225 mg/day) combined with either low-dose (330 mg/day) or high-dose (990 mg/day) aspirin.
Measured 51Cr-labelled platelet survival in 20 patients (group I) after placebo and high-dose combination therapy, and measured platelet-regeneration times across all four treatment regimens in 7 patients (group II).
In group I, high-dose aspirin plus dipyridamole significantly prolonged platelet survival from 7.3 ± 0.2 days on placebo to 8.4 ± 0.1 days (mean ± SEM, P < 0.001).
In group II, platelet regeneration time was significantly prolonged compared to placebo (7.2 ± 0.2 days) only by high-dose aspirin plus dipyridamole (9.8 ± 0.5 days, P < 0.01), with no significant prolongation from low-dose combination therapy (8.3 ± 0.5 days) or aspirin alone (7.3 ± 0.3 days).

Structured PICO

Does aspirin alone or in combination with dipyridamole prolong platelet survival in insulin-dependent diabetic patients with severe retinopathy?

Population

27 insulin-dependent diabetic patients with severe retinopathy

Intervention

Aspirin (990 mg/day) alone, or a combination of dipyridamole (225 mg/day) with aspirin at two dosage levels (330 mg/day and 990 mg/day)

Comparator

Placebo

Outcome

51Cr-labelled-platelet survival and platelet-regeneration timessurrogate

High-dose aspirin combined with dipyridamole significantly prolongs platelet survival in diabetic patients with severe retinopathy, suggesting that reducing aspirin doses below 1 g/day in this combination may reduce its antithrombotic efficacy on this surrogate marker.

Cite This Study

Tindall et al. (1982) studied this question.

synapsesocial.com/papers/6a8c446cf8241cb45bfb8b2c https://doi.org/10.1042/cs0630205

View Full Paper

Ask AI

Bookmark

Implication

High-dose aspirin/dipyridamole prolongs platelet survival in diabetic retinopathy; supports ~1 g/day dosing on this surrogate but needs outcome trials.

Aspirin, Dipyridamole and Platelet Survival in Patients with Diabetes Mellitus

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Aspirin, Dipyridamole and Platelet Survival in Patients with Diabetes Mellitus

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider